Endometriosis is considered to be an estrogen-dependent inflammatory disease, but its etiology is unclear. Thus far, a mechanistic role for steroid receptor coactivators (SRCs) in the progression of endometriosis has not been elucidated. An SRC-1-null mouse model reveals that the mouse SRC-1 gene has an essential role in endometriosis progression. Notably, a previously unidentified 70-kDa SRC-1 proteolytic isoform is highly elevated both in the endometriotic tissue of mice with surgically induced endometriosis and in endometriotic stromal cells biopsied from patients with endometriosis compared to normal endometrium. Tnf −/− and Mmp9 −/− mice with surgically induced endometriosis showed that activation of tumor necrosis factor a (TNF-a)-induced matrix metallopeptidase 9 (MMP9) activity mediates formation of the 70-kDa SRC-1 C-terminal isoform in endometriotic mouse tissue. In contrast to full-length SRC-1, the endometriotic 70-kDa SRC-1 C-terminal fragment prevents TNF-a-mediated apoptosis in human endometrial epithelial cells and causes the epithelial-mesenchymal transition and the invasion of human endometrial cells that are hallmarks of progressive endometriosis. Collectively, the newly identified TNF-a-MMP9-SRC-1 isoform functional axis promotes pathogenic progression of endometriosis.
The defining feature of endometriosis is that endometrial tissues deposit to and grow in sites outside of the uterine cavity 1 . The patho genesis of endometriosis remains under debate despite extensive research. Among the hypotheses are Sampson′s retrograde men struation theory, which proposes that endometrial cells are refluxed through the fallopian tubes during menstruation and then are implanted onto the peritoneum or pelvic organs. In addition to retro grade menstruation, however, other factors must be involved in the progression of endometriosis, as only 15% of all women of reproduc tive age have endometriosis even though retrograde menstruation is a common phenomenon.
Estrogen is considered to be one of the key modulators in the pathophysiology and/or pathogenesis of endometriosis because a considerable number of clinical reports have defined endometrio sis as an estrogendependent disease 2, 3 . The estrogendependent growth of endometriotic tissue is enhanced by high local estrogen concentrations that are mediated by aromatase 4 . Therefore, drugs that suppress estrogen production, such as gonadotropinreleasing hormone analogs and aromatase inhibitors, have been used in endometriosis treatments [5] [6] [7] . In addition to the elevation of local estrogen concentrations, the upregulation of the estrogen receptor β (ERβ) concentrations in endometriotic tissue is correlated with the progression of endometriosis 8 . The regulation of ERβ activity by selective estrogen receptor modulators has also been proffered as a potential treatment for endometriosis 9, 10 . For example, treatment with ERB041 (an ERβ-selective agonist) regressed ectopic lesion growth in mice with endometriosis 9 . Nevertheless, the role of ERβ in the estrogendependent progression of endometriosis has not been clearly elucidated.
Proinflammatory signaling also has an essential role in the progres sion of endometriosis because a number of cytokines in the perito neal fluid of patients with endometriosis are actively involved in the pathogenesis and progression of the disorder 11, 12 . Interference with the proinflammatory signaling in the peritoneal fluid has been used to suppress ectopic lesion growth. For example, treatment with a mono clonal antibody to tumor necrosis factor α (TNFα) (c5N) in baboons with endometriosis substantially reduces the extent of endometriosis progression 13 . Nonsteroidal antiinflammatory drugs, such as ibupro fen, also have been used for the treatment of endometriosis 14 .
To advance their progression, endometriotic cells express aberrant, elevated concentrations of matrix metalloproteinases (MMPs) during their migration to, and implantation in, distinct anatomical sites 15 . Therefore, the inhibition of MMP activity by MMP inhibitor III may prevent the progression of endometriosis 16 .
To precisely respond to external hormonal stimuli, SRCs dynamically modulate nuclearreceptor-mediated cellular processes in a tissue selective manner. Accordingly, altered concentrations of SRCs and nuclear receptors in specific target tissues are frequently associated with human disease progression 17 . In endometriosis, lower fulllength SRC1 protein concentrations have been reported in endometriotic tissue compared to normal endometrium 18, 19 . However, the role of SRC1 in the progression of endometriosis has not been elucidated. Therefore, the object of this study was to investigate the functional role of the SRC1 gene in the progression of endometriosis. Based on our results, we suggest that a newly identified SRC1 isoform can be a new molecular target for therapy of this disease.
RESULTS

Endometriotic tissues contain a 70-kDa SRC-1 isoform
To investigate the role of SRCs in the progression of endometriosis, we used C57BL/6J mice with surgically induced endometriosis (SIE) 20 in parallel with primary human endometriotic stromal cells isolated from individuals who received a diagnosis of endometriosis. In our C57BL/6J mouse model, we successfully implanted endometrial frag ments that eventually progressed to ectopic lesions in an estrogen dependent manner in recipient C57BL/6J mice ( Supplementary  Fig. 1a,b) . Next we determined the expression of cyclooxygenase2 (COX2) to validate the progression of endometriosis; COX2 has been reported to be elevated in endometriotic endometrium com pared to normal endometrium 21 . We found that endometriotic tissues of mice with SIE had higher COX2 expression relative to the uterine tissue from shamtreated mice (Supplementary Fig. 1c ). To inves tigate the expression profiles of SRCs in normal and endometriotic tissues, we divided the mice into two groups: sham treated, referring to the uterine tissue from ovariectomized mice that we treated with estradiol (E2) pellets and surgery but in which we did not implant an endometrial fragment; and endometriosis, referring to the ectopic and eutopic endometrium of ovariectomized mice with SIE in the presence of E2 pellets (Fig. 1a) . We found that the uterine tissue of the shamtreated mice had a 160kDa intact SRC1 protein (Fig. 1a) . However, the ectopic and eutopic endometrium of mice with SIE had lower amounts of fulllength SRC1 but higher amounts of a 70kDa truncated form of SRC1 compared to the shamtreated uterine tissue (Fig. 1a,b) . To evaluate the nature of the 70kDa fragment, we isolated uteri from ovariectomized SRC1-null mice treated with E2 pellets. The uterine tissue from the SRC1-null mice did not have intact fulllength SRC1 or the 70kDa SRC1 fragment (Fig. 1c) . Therefore, the 70kDa fragment was substantiated as an isoform of SRC1. An immunostaining analysis revealed that SRC1 isoform had similar endometrialcompartment-specific expression patterns (for example, in the luminal epithelium and stroma) as those of full length SRC1 in normal endometrium (Fig. 1d) . However, we found that shamtreated uterine tissue primarily had an intact SRC1 in the nuclei, but endometriotic tissue had the 70kDa SRC1 isoform in both the cytoplasm and the nuclei (Fig. 1d) .
We then examined whether human endometriotic tissue also con tained the 70kDa SRC1 isoform. We determined an SRC1 expression profile in primary human endometrial stromal cells (HESCs) isolated from women without endometriosis (n = 3) and women with endome triosis (n = 10). We found that eight of ten primary HESCs from women with endometriosis had higher amounts of this 70kDa trun cated SRC1 form compared to the primary HESCs of women without endometriosis (Fig. 1e,f and Supplementary Fig. 2a) . Consistent with the findings in the SRC1-null mice, SRC1 knockdown in HESCs from women with endometriosis validated that the 70kDa fragment is an SRC1 isoform in humans (Supplementary Fig. 2b ). We then examined whether an external hormone changed the amount of the 70kDa SRC1 isoform in human endometriotic stromal cells. We found that treatment with estrogen, progesterone or a combination of the two did not change the amount of the SRC1 isoform in primary human endometriotic stromal cells in cell culture ( Supplementary  Fig. 2d-h ). Primary human endometriotic stromal cells had variable (f-h) The ratio of the SRC-1 isoform (SRC-1 iso) to tubulin (f), of ER-β to tubulin (g) and of ER-α to tubulin (h) in cultured primary HESC lines isolated from women without endometriosis (n = 3) and from the ectopic and eutopic endometrium from women with endometriosis (n = 10). *P < 0.05, **P < 0.01 by Student's t test. Scale bars, 50 µm. ratios of the SRC1 isoform to fulllength SRC1 ( Fig. 1e and Supplementary Fig. 2a) . However, further examination of informa tion about the subjects from which these cells came ( Supplementary  Fig. 2c ) revealed that the differential ratio of the SRC1 isoform to full length SRC1 was correlated with the site of biopsy. We detected the SRC1 isoform predominantly in HESCs isolated from ectopic lesions of women with endometriosis (Fig. 1e) . However, we found a low ratio of the SRC1 isoform to fulllength SRC1 in the HESCs of the eutopic endometrium from these women (Supplementary Fig. 2a) . Therefore, ectopic lesions had a higher SRC1 processing activity compared to the eutopic endometrium. Also, the menstrual cycle did not affect the ratio of the SRC1 isoform to fulllength SRC1. In addition to the uterus, endometriosis affected the SRC1 milieus of other organs of the abdominal cavity: the intestine and liver of mice with SIE had higher amounts of the endometriotic SRC1 isoform compared to shamtreated mice (Supplementary Fig. 2i ). We also found that the primary HESCs of women with endometriosis had higher expression of ERβ compared to normal primary HESCs, as has been described previously (Fig. 1e,g and Supplementary Fig. 2a ) 22, 23 . In contrast to ERβ, however, we found that the expression of ERα was the same in HESCs of women with endometriosis as in HESCs of women without endometriosis (Fig. 1e,h and Supplementary Fig. 2a) .
In addition to SRC1, we found that endometriotic mouse tissue also had various altered forms of SRC2 and SRC3 ( Supplementary  Fig. 3a,b) . However, only the ectopic lesions, and not the eutopic endometrium, had truncated forms of SRC2 (110 kDa) and SRC3 (85 kDa) in mice with SIE. In contrast to the SRC1 isoform, we found that HESCs isolated from the ectopic lesions of women with endometriosis did not have the altered forms of SRC2 and SRC3 ( Supplementary Fig. 3c,d) . Collectively, these data reveal that mouse and human endometriotic tissues have the 70kDa SRC1 isoform but not the altered forms of SRC2 and SRC3.
Notably, we found that SRC2-null and SRC3-null ectopic lesions had a lower ectopic lesion volume compared to wildtype ectopic lesions in mice with SIE (Supplementary Fig. 3e) . Therefore, the SRC2 and SRC3 genes might have a permissive or cooperative role with the SRC1 isoform to modulate the growth of ectopic lesions in mice with SIE.
Mouse SRC-1 modulates the progression of ectopic lesions The finding of the endometriotic SRC1 isoform raised the question of whether it is required for endometriosis to develop. To address this issue, we surgically induced endometriosis using SRC1-null mice. We transplanted the endometrial tissue fragments generated from the uteri of SRC1-null mice or congenic C57BL/6J mice into ovariec tomized C57BL/6J recipient mice treated with E2 pellets to induce endometriosis. We found that the endometrial tissue fragments from C57BL/6J donors successfully developed into ectopic lesions (Fig. 2a) . However, the deletion of the mouse SRC-1 gene resulted in lower volumes of ectopic lesions by over 500% compared to the wildtype ectopic lesions (Fig. 2a,b) . Therefore, the mouse SRC-1 gene is an essential factor for the growth of ectopic lesions. SIE, we used GFP transgenic mice (C57BL/6Tg(CAGGFP)10sb/J) that ubiquitously express GFP in all tissue types. To obtain SRC1-null uterine tissue that expressed GFP, we generated bigenic SRC1 null; GFP mice by crossing SRC1-null mice with the GFPexpressing transgenic mice. We isolated the wildtype and SRC1-null uterine fragments expressing GFP and then implanted them into ovariec tomized C57BL/6J recipient mice treated with E2 pellets to induce endometriosis. After the progression of endometriosis, we detected ectopic lesions expressing GFP in the mesenteric membrane of recipi ent mice under a fluorescence dissecting microscope (Fig. 2c) . The SRC1-null ectopic lesions had a lower density of GFP compared to the wildtype ectopic lesions (Fig. 2d) .
To further analyze the growth defects in the ectopic lesions stem ming from SRC1-null endometrial fragments, we determined the expression of COX2 and of the vascular endothelial growth factor receptor (VEGFR) because endometriotic tissues have higher COX2 and VEGFR expression relative to normal tissues 24, 25 . We found that SRC1-null ectopic lesions had lower expression of both endometrio sis marker genes compared to wildtype ectopic lesions (Fig. 2e) . In addition, an analysis of the concentration of phosphorylated histone H3 revealed that the SRC1-null ectopic lesions also had lower prolif erative activity relative to wildtype ectopic lesions (Fig. 2f) . However, we found that SRC1-null ectopic lesions had higher amounts of active caspase 3 compared to wildtype ectopic lesions (Fig. 2f) . In addition to ectopic lesions, we found that the proliferative activity and apoptosis signaling were also lower and higher, respectively, in SRC1-null eutopic endometrium compared to wildtype eutopic endometrium of mice with SIE ( Fig. 2g) . Collectively, these results suggest that the mouse SRC-1 gene has a similar effect on both the ectopic and eutopic endometrium of mice with SIE.
The derivation of the 70-kDa isoform of SRC-1 We next attempted to discern the exact origin of the SRC1 isoform in endometriotic tissue. A northern blot analysis with a probe against fulllength mouse SRC1 revealed that the SRC1 mRNA expression patterns in the eutopic endometrium of mice with SIE were the same as those in the shamtreated uterine tissue (Supplementary Fig. 4 ). This result implied that the SRC1 isoform is not an alternative RNA splicing variant but may be a posttranslational and sitespecific pro teasemediated proteolytic cleavage product.
To identify the SRC1 isoform, we used a heterologous mouse model of endometriosis with severe combined immune deficiency (SCID) mutant mice and immortalized human endometrial cells, as previously described 26 . We used immortalized human endometrial epithelial cells (IHEECs) obtained by stably transfecting the catalytic subunit (hTERT) of the human telomerase complex 27 and immortalized human endome trial stromal cell lines (IHESCs) generated by the transfection of hTERT using a retroviral system 28 . To determine whether the endometriotic SRC1 isoform contained the N terminus or the C terminus, we modi fied human SRC1 complementary DNA by adding a Flag tag on the Nterminal region and a MYC tag on the Cterminal region (resulting in a gene we refer to here as FSRC1M). Using this lentiviral vector con taining the FSRC1M gene, we modified IHEECs and IHESCs to stably express the exogenous FSRC1M gene. To efficiently induce endome triosis in the SCID mouse model, we mixed and cultured recombinant IHESCs expressing FSRC1M with recombinant IHEECs expressing FSRC1M on Matrigel because paracrine communication between the stromal and epithelial compartments is a crucial factor for modulat ing endometrial function in vivo 29 . We then transplanted the mixed cultured recombinant human endometrial cells into the pelvic cavi ties of ovariectomized SCID mice treated with E2 pellets (Fig. 3a) . To precisely analyze the exogenous FSRC1M processing pattern in ectopic lesions using antibodies to the Flag and MYC tags, we pro duced another type of ectopic lesion using the transplantation of mixedcultured parental IHESCs and IHEECs into SCID mice because ectopic lesions that are developed from the parental human endometrial cells do not express FSRC1M (Fig. 3a) . We found that the ectopic lesions were well developed in ~80% of the SCID mice that we transplanted with mixedcultured human endometrial cells (Supplementary Fig. 5a-c) . Immunostaining with antibodies to vimentin (an endometrial stromal cell biomarker) and cytokeratin 18 (an endometrial epithelial cell biomarker) revealed that ectopic lesions successfully developed from mixed cultures of IHEECs and IHESCs (Supplementary Fig. 5d-f) . In addition, we found that human ectopic lesions developed in SCID mice had higher expressions of several endometriosis marker genes (such as the ERβ, VEGFR2 and COX2 genes) compared to the mixedcultured human endometrial cells (Fig. 3b) . Therefore, the mixedcultured IHEECs and IHESCs successfully developed into typical ectopic lesions in SCID mice.
For the identification of the SRC1 isoform present in the ectopic lesions that developed in the SCID mice, we conducted a western blot analysis with antibodies to the Flag or MYC peptides. We found that the antibody to Flag did not detect the 70kDa SRC1 isoform or any SRC1 fragments of other sizes in recombinant ectopic lesions expressing FSRC1M (Fig. 3c) . In contrast to the antibody to Flag, however, the antibody to MYC recognized the 70kDa protein in recombinant ectopic lesions expressing FSRC1M but not in the control ectopic lesions expressing no FSRC1M (Fig. 3d) . We found that this 70kDa fragment containing the MYC tag in recombinant ectopic lesions was also recognized by the antibody to SRC1 that we used for the detection of the 70kDa SRC1 isoform in endometri otic mouse tissue (Fig. 3e) . Therefore, the 70kDa SRC1 isoform in endometriotic tissues is a posttranslational proteolytic Cterminal isoform of SRC1.
The TNF-a-MMP9 axis generates endometriotic SRC-1 isoform A protease cleavage site prediction program (http://pops.csse.monash. edu.au/popscgi/index.php) indicated that MMP9 can generate the 70kDa SRC1 Cterminal isoform from intact SRC1 because SRC1 has a potential MMP9 cleavage site at P790M791. A gelatin zymogra phy analysis revealed that the eutopic endometrium of mice with SIE and the primary HESCs from women with endometriosis had higher MMP9 activity compared to the endometrium of shamtreated mice and normal HESCs, respectively (Fig. 4a,b) . In contrast to MMP9, however, both mouse and human endometriotic cells had very limited MMP2 activity (Fig. 4a,b) . The inhibition of MMP9 activity by treat ment with an inhibitor of MMP2 and MMP9 (MMP2/MMP9 inhibi tor III) reduced the volume of the ectopic lesions in mice with SIE and did not produce the endometriotic 70kDa SRC1 Cterminal isoform in the eutopic endometrium (Fig. 4c-e) . In addition to treatment with the MMP2/MMP9 inhibitor, the Mmp9 gene also had an essential role in ectopic lesion growth because ectopic lesions in Mmp9 −/− mice with SIE had a lower ectopic lesion volume compared to the wildtype ectopic lesions in congenic FVB/NJ mice (Supplementary Fig. 6a ). In addition to the regression of ectopic lesion growth, we found that the eutopic endometrium of Mmp9 −/− mice with SIE did not have the endometriotic SRC1 isoform whereas eutopic endometrium of the congenic FVB/NJ mice with SIE did (Supplementary Fig. 6b) . Collectively, these results suggested that MMP9 has an essential role in both ectopic lesion growth and the generation of the SRC1 Cterminal isoform in the endometriotic tissue of mice with SIE.
How is MMP9 activity regulated in endometriotic tissues during the progression of endometriosis? Previous studies revealed Figure 4 The TNF-α-MMP9 functional axis had an essential role in the progression of endometriosis and the formation of the endometriotic SRC-1 isoform in endometriotic tissue. (a) Gelatin zymography analysis of MMP9 and MMP2 activity in the uterus of sham-treated mice and in the eutopic endometrium of mice with SIE and the ratio of MMP9 activity to tubulin in each type of endometrium (n = 4 per group). (b) Gelatin zymography analysis of MMP9 and MMP2 activity in primary HESCs isolated from women without endometriosis (W/O endometriosis) and from women with endometriosis (W/ endometriosis) and the ratio of MMP9 activity to tubulin in each type of cell (n = 3 per group). (c) Gelatin zymography analysis of MMP9 activity in the eutopic endometrium of C57BL/6J mice with SIE treated with vehicle or MMP2/MMP9 inhibitor III (MMP2/9 in.) and the ratio of MMP9 activity to tubulin in each eutopic endometrium (n = 4 per group). (d) Ectopic lesions isolated from mice with SIE treated with vehicle or MMP2/MMP9 inhibitor III and a volume analysis of each isolated ectopic lesion (n = 4 per group). (e) Western blot analysis of the SRC-1 expression patterns in the eutopic endometrium of mice with SIE treated with vehicle or MMP2/MMP9 inhibitor III and the ratio of the 70-kDa SRC-1 isoform to intact SRC-1 in each type of endometrium. (f) Gelatin zymography analysis of MMP9 activity in the eutopic endometrium of Tnf −/− mice and congenic wild-type mice with SIE and the ratio of MMP9 activity to tubulin in each type of eutopic endometrium (n = 3 per group). (g) Ectopic lesions isolated from congenic wild-type mice and Tnf −/− mice with SIE and a volume analysis of each isolated ectopic lesion (n = 4 per group). (h) Western blot analysis of the expression patterns of SRC-1 in the eutopic endometrium of Tnf −/− mice and congenic wild-type mice with SIE and the ratio of the 70-kDa SRC-1 isoform to intact SRC-1 in each type of eutopic endometrium (n = 3 per group). **P < 0.01, ***P < 0.001 by Student's t test. npg that proinflammatory signaling is closely associated with tissue remodeling pathways in inflammatory disease progression. For example, TNFα induces the expression of invasion mediators, such as MMPs, to promote cell mobility 30 . In our mouse model, we also found that the eutopic and ectopic endometrium of mice with SIE had higher concentrations of TNFα compared to normal endometrium (Supplementary Fig. 6c) . Notably, gelatin zymography revealed that the eutopic endometrium of Tnf −/− mice with SIE had lower MMP9 activity than congenic wildtype mice with SIE (Fig. 4f) . In addi tion to the lower MMP9 activity, we found that Tnf −/− mice with SIE had lower volumes of ectopic lesions than congenic wildtype mice with SIE (Fig. 4g) . The eutopic endometrium of Tnf −/− mice with SIE did not have the SRC1 isoform whereas the endometrium of wild type mice with SIE did (Fig. 4h) . Collectively, these results suggested that the induction of TNFα signaling activates MMP9 to promote ectopic lesion growth and generate the SRC1 Cterminal isoform in endometriotic tissue.
The above observation raised the issue of whether SRC1 is a direct substrate for MMP9 in endometriotic tissue. To address this, we conducted in vitro MMP9 processing assays with the purified doubletagged FSRC1M protein and activated recombinant MMP9 protein. The antibody to Flag revealed that recombinant MMP9 generated a 60kDa Nterminal SRC1 fragment in vitro (Fig. 5a) . However, the human ectopic lesions that developed in SCID mice did not have this Nterminal SRC1 fragment in vivo (Fig. 3c) . In contrast to the antibody to Flag, MYC specific antibody detected the 70kDa SRC1 Cterminal isoform (Fig. 5b) . We found that this 70kDa SRC1 Cterminal fragment also was recognized by an SRC1-specific anti body that has been used for the detection of SRC1 isoforms in mouse endometriotic tissue (Fig. 5c) . Therefore, MMP9 directly recognized SRC1 and processed it to the 70kDa SRC1 Cterminal isoform in vitro. In contrast to MMP9, however, MMP2 did not produce the 70kDa SRC1 Cterminal isoform in vitro (Supplementary Fig. 6d) .
The protease prediction program (http://pops.csse.monash. edu.au/popscgi/index.php) revealed that MMP9 can recognize the P790M791 dipeptide in SRC1 to process the 70kDa SRC1 Cterminal isoform. To confirm this prediction, we substituted Pro790 with alanine to generate an MMP9cleavage-defective SRC1 mutant (Pro790Ala) that had a Flag tag in the Nterminal region and a MYC tag in the Cterminal region. An in vitro MMP9 processing assay with the purified SRC1 Pro790Ala mutant revealed that MMP9 also generated the same 60kDa Nterminal SRC1 fragment from the mutant as we found in wildtype SRC1 (Fig. 5d) . However, a western blot analysis with the MYCspecific antibody revealed that MMP9 did not generate the 70kDa SRC1 Cterminal isoform from the SRC1 Pro790Ala mutant in vitro (Fig. 5e) . The antibody to SRC1 also did not recognize the 70kDa fragment from the SRC1 Pro790Ala mutant after incubation with MMP9 (Fig. 5f ). These findings indicated that MMP9 cleaved SRC1 at the P790M791 site to produce the 70kDa SRC1 Cterminal isoform in vitro. The above observation raised the question of whether MMP9 also cleaves the P790M791 site of SRC1 to produce the SRC1 Cterminal isoform in endometriotic tissue in vivo. To address this, we transplanted mixed cultures of recombinant IHEECs stably express ing the FSRC1M Pro790Ala mutant and IHESCs into SCID mice to induce ectopic lesions (Fig. 5g) . A western blot analysis with the MYCspecific antibody revealed that ectopic lesions did not generate the 70kDa isoform from the FSRC1M Pro790Ala mutant (Fig. 5h) .
Taken together, these results suggest that MMP9 cleaves at the P790 M791 site of SRC1 to generate the 70kDa SRC1 Cterminal isoform in endometriotic tissue (Fig. 5i) .
The 70-kDa SRC-1 isoform and endometriosis progression What is the differential role of the SRC1 Cterminal isoform compared to fulllength SRC1 in endometriotic tissue? To address this question, we generated IHEECs that stably expressed the SRC1 Cterminal isoform (amino acids 791-1,441) using a lentivirus mediated gene transfer protocol (Supplementary Fig. 7a ). An immunostaining analysis revealed that the SRC1 Cterminal iso form was located in both the nuclear and cytoplasmic compartments of these IHEECs (Supplementary Fig. 7b ).
In nuclearreceptor-mediated signaling, the SRC1 Cterminal isoform interacted with ERα, ERβ and progesterone recep tor (Supplementary Fig. 8a-c) and activated ERα-, ERβ-and progesteronereceptor-mediated gene transcription, as did fulllength SRC1 (Supplementary Fig. 8d-g ).
The endometriosisassociated proinflammatory pelvic environ ment normally causes cell death, such that menstrual cell masses are cleared. Therefore, the evasion of TNFα-induced cell death is an essential step for the development of stable ectopic lesions during the progression of endometriosis. We therefore investigated the role of the SRC1 Cterminal isoform in the evasion of TNFα-induced cell death. The parental IHEECs and two different recombinant IHEECs expressing fulllength SRC1 or the SRC1 isoform grew well under vehicle treatment (Fig. 6a) . However, treatment with 10 ng ml −1 of TNFα for 2 d prevented the growth of parental (Fig. 6a,b) and recombinant IHEECs expressing fulllength SRC1 (Fig. 6a,c) compared to the vehicle treatment. In contrast, however, IHEECs expressing the SRC1 Cterminal isoform did not have a sub stantial amount of TNFα-induced growth inhibition compared to the parental IHEECs and those expressing fulllength SRC1 (Fig. 6a,d) . Therefore, we concluded that the endometriotic SRC1 Cterminal isoform prevented the TNFα-induced growth inhibition of IHEECs.
The activation of the apoptosis pathway mediated by caspase 8, caspase 3 and truncated BH3 interactingdomain death agonist (tBid) has a key role in TNFα-induced growth inhibition 31 . Therefore, we examined whether the expression of the endometriotic SRC1 isoform inhibited TNFα-induced apoptosis signaling in IHEECs. Consistent with previous observations, we found that TNFα treatment led to higher amounts of cleaved caspase 8, tBid and activated caspase 3 in parental IHEECs as compared to parental IHEECs treated with vehicle (Fig. 6e,f) . Notably, after treatment with TNFα, the recombinant IHEECs expressing fulllength SRC1 had higher expression of these apoptosis markers relative to the parental IHEECs (Fig. 6e,f) . In con trast, however, recombinant IHEECs expressing the SRC1 Cterminal isoform did not have higher amounts of cleaved caspase 8, tBid and activated caspase 3 as a result of TNFα treatment than the parental and recombinant IHEECs expressing fulllength SRC1 (Fig. 6e,f) . To determine how the SRC1 isoform inhibits TNFα-induced apoptosis in IHEECs, we performed a coimmunoprecipitation assay. We found that the SRC1 Cterminal isoform, but not fulllength SRC1 (FSRC 1M or endogenous SRC1), interacted with procaspase 8 in IHEECs in both the absence and presence of TNFα (Fig. 6g) . Therefore, we concluded that the SRC1 Cterminal isoform protected the IHEECs from TNFα-induced apoptosis by interacting with procaspase 8 to prevent its activational processing.
In addition to the evasion of TNFα-induced cell death, the exten sive invasion of ectopic endometrium into target tissues (such as the ovary, uterus, intestine and bladder) is another essential step in the progression of endometriosis. We found that the recombinant IHEECs expressing fulllength SRC1 had higher invasive capacity than the parental IHEECs (Fig. 6h) . However, we found that the inva sive capacity of the IHEECs was more enhanced by the overexpres sion of the endometriotic SRC1 Cterminal isoform compared to the overexpression of fulllength SRC1 (Fig. 6h) .
The epithelialmesenchymal transition (EMT) has a key role in metastasis and is characterized by the conversion of epithelial cancer cells to a more motile phenotype that facilitates invasion. We therefore investigated whether the endometriotic SRC1 Cterminal isoform induced EMT in IHEECs to enhance the invasive capacity of these cells. We found that the recombinant IHEECs that overexpressed the endometriotic SRC1 Cterminal isoform had higher expression of many of the acquired markers of EMT (Ncadherin, vimentin, Slug, Snail, βcatenin and transcription factor 8 (TCF8)) when compared to parental IHEECs and to IHEECs overexpressing fulllength SRC1 in the absence or presence of TNFα treatment (Fig. 6i) . Therefore, the SRC1 isoform enhanced EMT to facilitate invasion by the ectopic endometrium during the progression of endometriosis.
In summary, to efficiently promote endometriosis, the activated TNFα-MMP9 axis processes SRC1 to its Cterminal isoform to protect the ectopic endometrium from a proinflammatory cytokinemediated cell death, which is then accompanied by EMT and the enhancement of the invasive capacity of the ectopic endometrium (Fig. 6j) .
DISCUSSION
Despite their wellknown and essential role in estrogen and progesteronemediated cellular processes, the role of SRCs in the progression of endometriosis has not been well studied. Here we propose a new TNFα-MMP9-SRC1 isoform functional axis as a previously unknown pathogenic pathway for endometriosis. The SRC1 isoform promotes endometriosis progression by causing EMT and the invasion of endometrial epithelial cells. An accompanying alteration of proinflammatory signaling is closely associated with inflammatory diseases and cancer progression because proinflam matory signaling changes the molecular properties of target cells 32, 33 . For example, treatment with TNFα changes the responsiveness to steroid hormones of uterine smooth muscle cells by suppressing the expression of SRC1 and SRC2 (ref. 34) . In the present study, we found that TNFα also changes the molecular properties of SRC1 through proteolytic processing to a 70kDa form that protects ectopic lesions from immune surveillance. Collectively, these results suggest that TNFα signaling has an essential role in the initiation of endometriotic cellular processes. In addition to uterus, the TNFα-induced inflammatory response to endometriosis can affect the SRC1 milieus of other organs of the abdominal cavity, such as the intestine and liver. In this way, endometriosis can be accompanied by serious harmful systemic effects that are secondary to a widespread inflammatory response.
We found that MMP9, induced by TNFα, is responsible for processing SRC1 to the 70kDa isoform. It was previously suggested that MMPs are secreted and then activated to remodel the mesothelial lining of the peritoneum and allow tissue invasion during the pro gression of endometriosis 35 . However, we detected the activities of both proMMP9 and processed MMP9 in the eutopic endometrium of mice with SIE. These data imply that the intracellular activation of MMP9 can occur within endometriotic tissue. Supporting our con clusion, the colocalization of trypsin2 and MMP9 has been reported in intracellular proMMP9 processing, which causes full or partial activation of MMP9 activity in the intracellular vesicles of carcinoma cells 36 . Therefore, it is probable that intracellular MMP9 activation in endometriosis is performed by a specific TNFα-induced protease to process SRC1 for the progression of endometriosis. In addition to the proteolytic activity of MMP9, the nonproteolytic activity of MMP9 may be involved in the progression of endometriosis because nonproteolytic MMP9 activity is associated with cell migration 37 . Proinflammatory signaling is frequently associated with tissue remodeling pathways in other inflammatory diseases and in cancer. For example, TNFα-induced MMP9 activation is associated with the progression of various cancers 38 . Therefore, the TNFα-MMP9 func tional axis may have an essential role not only in endometriosis but also in other types of inflammatory diseases and cancer. Consequently, this functional axis should be considered a new molecular therapeutic target for the treatment of these diseases.
What is the pathobiological function of the antiapoptotic process ing mediated by the SRC1 Cterminal isoform in human endome trial epithelial cells during the progression of endometriosis? The communication between the epithelial and stromal compartments has an essential role in endometrial function. Therefore, paracrine factors produced from stromal cells regulate cellsurvival signaling in epithelial cells in the normal endometrium. In endometriosis, paracrine factors are also released from stromal cells to modulate cellsurvival signaling in epithelial cells in the endometriotic eutopic endometrium 39 . In contrast to the eutopic endometrium, however, ectopic stromal cells lose the ability to regulate cellsurvival signaling in ectopic epithelial cells 39 . Therefore, epithelial cells in ectopic lesions must acquire a new cellsurvival system. In this context, epithelial cells in ectopic lesions activate the TNFα-MMP9-SRC1 isoform pathway in response to TNFα during the progression of endome triosis. The activation of this pathway processes SRC1 to the SRC1 Cterminal isoform, protecting epithelial cells in ectopic lesions from TNFα-induced cell death and, thus, promoting their survival. In this way, the activation of the TNFα-MMP9-SRC1 isoform pathway in ectopic lesions can compensate for the loss of paracrine survival signaling generated from ectopic stromal cells.
Endometriosis is known as an estrogendependent inflamma tory disease. What is the role of the SRC1 Cterminal isoform in the estrogendependent nature of endometriosis? Ectopic lesions require estrogendependent cellular processes for growth. However, ectopic lesions cannot use SRC1 for estrogendependent gene regulation because fulllength SRC1 led to an increase in TNFα-mediated cell death in IHEECs. For survival, SRC1 must be processed to the SRC1 Cterminal isoform in the epithelial cells of ectopic lesions to modulate estrogendependent cellular pro cesses during activated proinflammatory signaling. In this way, the endometriosisinduced microenvironment actively changes the molecular properties of SRC1 by proteolytic processing to prevent apoptosis but can still allow an estrogendependent progression of endometriosis.
We propose that this newly identified TNFα-MMP9-SRC1 Cterminal isoform functional axis is a new pathogenic pathway for the progression of endometriosis that has potential as a therapeutic target for endometriosis therapy. Indeed, antitumor necrosis factor therapy (etanercept) effectively reduces the development of endome triosis in an experimental rat model 40 . This observation further sup ports an essential role for the TNFα-MMP9-SRC1 Cterminal isoform functional axis in the progression of endometriosis.
METhODS
Methods and any associated references are available in the online version of the paper. 
